Treating TAMR cells with Decitabine, a demethylating agent, or Farudodstat, a pyrimidine biosynthesis inhibitor, markedly augmented the efficacy of tamoxifen. Restoring ASS1 expression or inhibiting pyrimidine biosynthesis reinstated tamoxifen sensitivity. ASS1 could be a potential biomarker and therapeutic target in tamoxifen-resistant ILC patients, warranting further investigation.

5 months ago

Journal

CDH1 (Cadherin 1) • ASS1 (Argininosuccinate synthase 1) • PRPS1 (Phosphoribosyl Pyrophosphate Synthetase 1) • PAICS (Phosphoribosylaminoimidazole Carboxylase And Phosphoribosylaminoimidazolesuccinocarboxamide Synthase)

tamoxifen • decitabine • farudodstat (ASLAN003)

10ms

Invasive lobular carcinoma integrated multi-omics analysis reveals silencing of Arginosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance. (PubMed, bioRxiv)

Treating TAMR cell with Decitabine, a demethylating agent, or Farudodstat, a pyrimidine biosynthesis inhibitor, markedly augmented efficacy of tamoxifen. Restoring ASS1 expression or inhibiting pyrimidine biosynthesis restored tamoxifen sensitivity. ASS1 could be a potential biomarker and therapeutic target in tamoxifen resistant ILC patients, warranting further investigation.

10 months ago

Journal

tamoxifen • decitabine • farudodstat (ASLAN003)

almost2years

FAST-AA: Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants (clinicaltrials.gov)

P2, N=60, Recruiting, ASLAN Pharmaceuticals | Phase classification: P2a --> P2 | Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Feb 2024 --> Sep 2024

almost 2 years ago

Phase classification • Trial completion date • Trial primary completion date

farudodstat (ASLAN003)

5years

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. (PubMed, Haematologica)

Our results, therefore, suggest that ASLAN003 is an agent targeting dihydroorotate dehydrogenase with potential in the treatment of acute myeloid leukemia. ASLAN003 is currently being evaluated in phase 2a clinical trial in acute myeloid leukemia patients.

5 years ago

Journal

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 mutation

farudodstat (ASLAN003)